Research and Markets (http://www.researchandmarkets.com/research/h65mff/fluzone)
has announced the addition of GlobalData's new report "Fluzone
IntraDermal (Seasonal Influenza Vaccines) Forecast and Market Analysis"
to their offering.
GlobalData has released its new PharmaPoint Drug Evaluation report,
Fluzone IntraDermal (Seasonal Influenza Vaccines) Forecast and Market
Analysis. Seasonal Influenza is a respiratory infection caused by
influenza virus that results in mild to severe symptoms, such as fever,
cold and cough. The market is heavily driven by the sales of
prophylactic vaccine treatments to prevent infection. Currently,
trivalent intramuscular vaccines such as Sanofi's Fluzone and Vaxigrip,
GlaxoSmithKline's Fluarix and FluLaval and Novartis' Fluvirin garner the
majority stake of the market. However, with the entrance of vaccines
with novel routes of administration, such as AstraZeneca's intranasal
FluMist and Sanofi's Fluzone IntraDemal, GlobalData projects a dramatic
shift favoring the adoption of such vaccines over the traditional
intramuscular vaccines. GlobalData also anticipates that manufacturers
that launch quadrivalent formulations will steal market share, patient
share, and revenue from the trivalent influenza vaccines currently
Fluzone ID is an inactivated, trivalent influenza vaccine that is
administered via intradermal injection. Fluzone ID's production is
similar to other inactivated, split virus influenza vaccines, but its
route of administration differentiates it from its competitors. This
novel route of administration uses a needle that is 90% smaller than the
one used for intramuscular injection. The site of injection (i.e., the
dermis) also has an increased number of immune cells compared to muscle
tissue, which results in a more robust immune response for intradermal
injection relative to intramuscular route of administration. Sanofi,
which distributes the vaccine in the US and Europe, hopes to leverage
these advantages to obtain patient share.
- Overview of seasonal influenza, including epidemiology, etiology,
symptoms, diagnosis, pathology and treatment guidelines as well as an
overview on the competitive landscape.
- Detailed information on Fluzone IntraDermal including product
description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Fluzone IntraDermal for four countries from 2012 to
- Sales information covered for the US, France, Germany and the UK.
Key Topics Covered:
1 List of Tables and Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
For more information visit http://www.researchandmarkets.com/research/h65mff/fluzone
[ Back To NFVZone's Homepage ]